-
2022-502732-39-00
10
2023-09-01
Previously treated non-ocular advanced melanoma
-
2024-511336-28-00
9
2023-08-11
Leukemia in childhood
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2022-500967-11-00
5
2023-07-06
Previously Untreated Metastatic or Unresectable Melanoma
-
2024-511794-30-00
9
2023-06-28
Multiple Myeloma
-
2022-501808-96-00
4
2023-05-15
Mantle Cell Lymphoma
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2023-505189-26-00
9
2023-03-28
Advanced esophageal squamous cell carcinoma
-
2022-501636-42-00
9
2023-03-21
Advanced RET-altered malignancies
-
2024-511219-78-00
5
2023-02-28
epithelial ovarian cancer
-
2024-515924-35-00
6
2023-01-16
New-Onset Post-Operative Atrial Fibrillation after CABG
-
2022-501090-39-00
5
2022-12-14
Biliary Atresia
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-517382-17-00
4
2022-11-30
Newly Diagnosed Multiple Myeloma in patients eligible for stem cell tr
-
2023-507041-28-00
4
2022-11-28
Solid and Hematological Malignancies
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2023-504484-16-00
9
2022-11-18
Multiple Myeloma (MM)
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma
-
2024-510990-21-00
10
2022-11-11
Mucopolysaccharidosis Type II [MPS II]
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n